MDCX

424B3 - Medicus Pharma Ltd. (0001997296) (Filer)

PRE 14A - Medicus Pharma Ltd. (0001997296) (Filer)

PHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the submission of an Orphan Drug Designation (ODD) application to the U.S. Food and Drug Administration for SkinJect® (D-MNA) for the treatment of basal cell carcinoma (BCC) in patients with Gorlin Syndrome, a rare genetic disorder characterized by the development of multiple, recurrent skin cancers. The submission represents a strategic expansion of the SkinJect program into a high unmet need orphan indication, where cu

PHILADELPHIA, April 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone (GnRH) antagonist, at the American Association of Clinical Endocrinology Annual Meeting 2026 (AACE 2026) on April 22-24th in Las Vegas, Nevada. Teverelix is being developed for hormone-driven conditions, with potential applications in women's health, including endometriosis and uterine fibroids. Faisal

PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the Company has submitted an optimized Phase 2 clinical study design to the U.S. Food and Drug Administration ("FDA") for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention ("AURr") in men with benign prostatic hyperplasia ("BPH") as part of its existing open Investigational New Drug ("IND") for Teverelix. The Phase 2 study design has been refined under the leadership

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

4 - Medicus Pharma Ltd. (0001997296) (Issuer)

PHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today issued a clarification regarding previously reported topline results from its Phase 2 clinical study of SKNJCT-003 in nodular basal cell carcinoma (BCC). SkinJect, an investigational doxorubicin-containing microneedle array (D-MNA), is being developed as a potential non-surgical treatment option for patients with nodular BCC, a common form of skin cancer currently treated primarily with surgical intervention. If confirmed in futu

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported independent clinical validation of its Phase 2 SkinJect® dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized dermatology key opinion leader.  Dr. Rao's independent assessment reinforces the Company's view that the dataset is clinically meaningful, decision-grade, and supportive of continued development and regulatory engagement. Dr. Rao, speaking in his capacity as princip

EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

PHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced it will host a business update conference call at 11:30 a.m. Eastern Time. The call will highlight new analysis from its Phase 2 SkinJect® study, including an overall response rate (ORR) of 80% in the 200µg cohort at Day 57, and outline the Company's planning toward an agentic AI–enabled clinical development platform. The Company believes these results position the 200µg cohort as the leading dose regimen in the study,

POS AM - Medicus Pharma Ltd. (0001997296) (Filer)